NeOnc’s FDA Catalyst Run Could Give NTHI a Serious Jolt
Globe Newswire•06/10/2026•09:02 ET
1
Key Highlights
- ➤NEO100 Phase 2a six-month progression-free survival reached 48.9% versus 20% benchmark
- ➤NEO100 Phase 2a median overall survival was 26.09 months
- ➤FDA Type B end-of-Phase 2 discussion for NEO100 anticipated in October
- ➤FDA End-of-Phase 1 Type B meeting for NEO212 scheduled November 17, 2026
- ➤Roth Capital initiated coverage with a Buy rating on September 24
Expert Statements
Jonathan Aschoff, Roth Capital analyst
“he anticipates an FDA Type B end-of-Phase 2 meeting for NEO100 in October”
Jonathan Aschoff, Roth Capital analyst
“pivotal trials potentially beginning before year-end”
DENVER, Oct. 06, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- A fall calendar is bringing NeOnc Technologies Holdings’ (NASDAQ: NTHI) investigational brain-cancer programs into focus.
Anticipation is building as Roth Capital’s recent Buy initiation adds another Wall Street voice to the NTHI story. With Roth anticipating an October FDA discussion for NEO100 and NeOnc’s November 17 meeting for NEO212 on the calendar, the coming weeks put the company’s clinical development plans firmly in the spotlight.
Get started
Create a free account to read the full story.